DiagnosticsPublished: May 2026Updated: May 20267 min read
LDL vs HDL Cholesterol: Which Number Matters More?
LDL vs HDL cholesterol is one of the most common questions we hear at our cardiology clinic at Paragon Medical Centre. Your lipid panel comes back from the lab with half a dozen numbers — and most patients are unsure which ones to focus on. The short answer, supported by decades of evidence and multiple large-scale trials: LDL is the primary driver of cardiovascular disease, and lowering it reduces risk in a dose-dependent, linear way. HDL is more complicated — observational data suggested it was protective, but clinical trials that raised HDL failed to reduce cardiac events. Understanding the full picture means knowing what each number actually does.
PC
Dr. Peter Chang
Triple Board-Certified Cardiologist & Vascular Specialist
LDL vs HDL: Which Number Actually Predicts Heart Disease?
The traditional ‘good cholesterol, bad cholesterol’ framing is directionally correct but dangerously oversimplified. LDL cholesterol (low-density lipoprotein) drives atherosclerosis — it is directly causal, dose-dependent, and the primary target of every cholesterol-lowering therapy that has demonstrated cardiovascular benefit. HDL cholesterol (high-density lipoprotein) is inversely associated with cardiovascular disease in population studies, but — and this is the critical distinction — artificially raising HDL through medication has consistently failed to reduce cardiac events.
Among the markers on a standard Singapore lipid panel, LDL is the one your cardiologist is most focused on. Non-HDL cholesterol (total cholesterol minus HDL) and apolipoprotein B are emerging as equally or more useful in certain patients, particularly those on statins. HDL remains a useful contextual marker but is no longer considered a therapeutic target.
Among the markers on a standard Singapore lipid panel, LDL is the one your cardiologist is most focused on. Non-HDL cholesterol (total cholesterol minus HDL) and apolipoprotein B are emerging as equally or more useful in certain patients, particularly those on statins. HDL remains a useful contextual marker but is no longer considered a therapeutic target.
- LDL-C: primary causal risk factor for atherosclerosis; the main therapeutic target
- HDL-C: inversely associated with CVD in epidemiology; not a useful drug target
- Non-HDL-C: captures all atherogenic lipoproteins; increasingly preferred as secondary target
- ApoB: best marker of total atherogenic particle burden; superior predictor in statin users
- Triglycerides: independently associated with CVD risk, especially when HDL is also low
How LDL Damages Your Arteries — and Why Every Reduction Counts
LDL particles are small enough to penetrate the endothelium — the inner lining of your arteries — and once there, they are oxidised and trigger a localised inflammatory response. This sets off the cascade of atherosclerosis: foam cells form, plaques accumulate, and arteries progressively narrow. The process takes decades, which is why many Singapore patients with high LDL feel entirely well until a cardiac event occurs.
The Cholesterol Treatment Trialists meta-analysis — 26 randomised trials, 170,000 participants — established that every 1 mmol/L reduction in LDL-C reduces major cardiovascular events by 22%, coronary death by 20%, and all-cause mortality by 10%. The FOURIER trial found risk reduction down to LDL levels below 0.4 mmol/L, with no safety floor. The relationship is linear and cumulative: the lower and longer, the better.
The Cholesterol Treatment Trialists meta-analysis — 26 randomised trials, 170,000 participants — established that every 1 mmol/L reduction in LDL-C reduces major cardiovascular events by 22%, coronary death by 20%, and all-cause mortality by 10%. The FOURIER trial found risk reduction down to LDL levels below 0.4 mmol/L, with no safety floor. The relationship is linear and cumulative: the lower and longer, the better.
- Each 1 mmol/L reduction in LDL-C → 22% fewer major CV events, 20% fewer coronary deaths (CTT meta-analysis)
- FOURIER trial: risk reduction continues below 0.4 mmol/L — no lower safety threshold identified
- Effect is dose-dependent and cumulative — duration of LDL lowering matters as much as magnitude
- Roughly one in three Singaporeans aged 40–69 have elevated LDL (National Population Health Survey)
The HDL Paradox: Why Raising Good Cholesterol Didn't Work
The Framingham Heart Study demonstrated a strong, graded, inverse relationship between HDL and cardiovascular disease — the higher the HDL, the lower the risk. This led to an obvious hypothesis: raise HDL pharmacologically and reduce cardiac events. The hypothesis was tested rigorously and it failed.
Three separate drug classes — niacin, fibrates, and CETP inhibitors — raised HDL substantially but produced no meaningful reduction in cardiovascular mortality or events in major randomised trials. Mendelian randomisation studies using genetic variants that naturally raise HDL showed no reduction in cardiovascular risk. The explanation: HDL function matters more than HDL quantity. In Singapore, patients who discover their HDL is 2.1 mmol/L should not interpret that as protection against a simultaneously elevated LDL.
Three separate drug classes — niacin, fibrates, and CETP inhibitors — raised HDL substantially but produced no meaningful reduction in cardiovascular mortality or events in major randomised trials. Mendelian randomisation studies using genetic variants that naturally raise HDL showed no reduction in cardiovascular risk. The explanation: HDL function matters more than HDL quantity. In Singapore, patients who discover their HDL is 2.1 mmol/L should not interpret that as protection against a simultaneously elevated LDL.
- Niacin, fibrates, CETP inhibitors: all raised HDL — none reduced CV mortality in major RCTs
- Mendelian randomisation: genetic HDL elevation does not reduce cardiovascular events
- Danish study (116,508 participants): U-shaped mortality curve — very high HDL (>2.5 mmol/L in men) paradoxically raises risk
- Meta-analysis of 68 cohorts (302,430 participants): no further CHD reduction with HDL above ~1.55 mmol/L (60 mg/dL)
Beyond LDL: When ApoB and Non-HDL Cholesterol Tell a Better Story
Apolipoprotein B (ApoB) is a protein carried by every atherogenic lipoprotein particle — LDL, VLDL, IDL, and Lp(a). Each particle carries exactly one ApoB molecule, which means ApoB directly counts the total number of atherogenic particles in circulation, regardless of how much cholesterol each particle carries. Two patients can have identical LDL-C levels but very different particle counts — and particle count is what drives plaque formation.
A 2025 systematic review covering 15 studies and 593,354 participants found ApoB and non-HDL-C showed superior cardiovascular risk prediction compared to LDL-C — particularly in statin-treated patients where discordance is most common. The National Lipid Association and ESC 2021 guidelines now recommend ApoB as an alternative or secondary target in high-risk patients. At our Singapore clinic, we measure ApoB routinely in patients on statins whose LDL appears controlled but whose overall risk profile remains concerning.
A 2025 systematic review covering 15 studies and 593,354 participants found ApoB and non-HDL-C showed superior cardiovascular risk prediction compared to LDL-C — particularly in statin-treated patients where discordance is most common. The National Lipid Association and ESC 2021 guidelines now recommend ApoB as an alternative or secondary target in high-risk patients. At our Singapore clinic, we measure ApoB routinely in patients on statins whose LDL appears controlled but whose overall risk profile remains concerning.
What Should Your Cholesterol Numbers Be? Singapore Targets
The right LDL target depends on your individual cardiovascular risk profile. The ESC/EAS 2021 Guidelines — which form the basis of cardiology practice in Singapore — stratify targets by risk tier:
Low risk (10-year CV risk <5%): LDL below 3.0 mmol/L. Moderate risk (5–10%): below 2.6 mmol/L. High risk (10–20%, or diabetes, CKD stage 3–4): below 1.8 mmol/L. Very high risk (established CVD, prior heart attack): below 1.4 mmol/L with at least 50% reduction from baseline. HDL targets are not specified as treatment goals — HDL below 1.0 mmol/L in men or 1.2 mmol/L in women is a risk marker warranting evaluation, not a drug target.
Low risk (10-year CV risk <5%): LDL below 3.0 mmol/L. Moderate risk (5–10%): below 2.6 mmol/L. High risk (10–20%, or diabetes, CKD stage 3–4): below 1.8 mmol/L. Very high risk (established CVD, prior heart attack): below 1.4 mmol/L with at least 50% reduction from baseline. HDL targets are not specified as treatment goals — HDL below 1.0 mmol/L in men or 1.2 mmol/L in women is a risk marker warranting evaluation, not a drug target.
- Low cardiovascular risk: LDL <3.0 mmol/L
- Moderate risk: LDL <2.6 mmol/L
- High risk (diabetes, CKD, 10-year risk 10–20%): LDL <1.8 mmol/L
- Very high risk (established CVD, prior MI or stroke): LDL <1.4 mmol/L with ≥50% reduction
- Low HDL (<1.0 mmol/L men; <1.2 mmol/L women): risk marker, not a drug target
Does a High HDL Mean You Are Protected? Not Always.
Many patients conclude that a high HDL level cancels out a high LDL level. The evidence does not support that conclusion. The Danish population study of 52,268 men and 64,240 women found a U-shaped relationship between HDL and all-cause mortality: risk is highest at low HDL, declines to a nadir, and then paradoxically rises again at very high HDL levels — above 2.5 mmol/L in men, above 3.0 mmol/L in women.
More practically: high HDL does not neutralise high LDL. Both are captured together in non-HDL cholesterol and ApoB measurements, which is part of why these markers are increasingly preferred. A Singapore patient with LDL of 3.8 mmol/L and HDL of 2.1 mmol/L has a meaningfully elevated atherogenic burden — not one that is cancelled out by the high HDL. The ESC recommends not using HDL as a risk measure when HDL exceeds 2.3 mmol/L (90 mg/dL), precisely because the protective relationship breaks down at that level.
More practically: high HDL does not neutralise high LDL. Both are captured together in non-HDL cholesterol and ApoB measurements, which is part of why these markers are increasingly preferred. A Singapore patient with LDL of 3.8 mmol/L and HDL of 2.1 mmol/L has a meaningfully elevated atherogenic burden — not one that is cancelled out by the high HDL. The ESC recommends not using HDL as a risk measure when HDL exceeds 2.3 mmol/L (90 mg/dL), precisely because the protective relationship breaks down at that level.
When to Get Your Cholesterol Checked in Singapore
The cholesterol blood test — a full fasting lipid panel — is one of the most cost-effective cardiovascular screening tools available. Singapore's Health Promotion Board recommends fasting lipid screening every three years for adults aged 18 and above, and more frequently for those with established risk factors or a family history of premature cardiovascular disease.
At Paragon Medical Centre on Orchard Road, a complete fasting lipid panel — including LDL, HDL, non-HDL, total cholesterol, triglycerides, and ApoB for higher-risk patients — is part of every cardiovascular risk assessment. Results are always interpreted in the context of your age, blood pressure, smoking status, family history, and diabetes risk, not as a standalone number. The printout is a starting point, not a verdict.
At Paragon Medical Centre on Orchard Road, a complete fasting lipid panel — including LDL, HDL, non-HDL, total cholesterol, triglycerides, and ApoB for higher-risk patients — is part of every cardiovascular risk assessment. Results are always interpreted in the context of your age, blood pressure, smoking status, family history, and diabetes risk, not as a standalone number. The printout is a starting point, not a verdict.
- Standard lipid panel: total cholesterol, LDL, HDL, non-HDL, triglycerides
- ApoB: recommended for high-risk patients and statin users with apparent LDL control
- HPB: screening every 3 years from age 18; annual review for those on lipid-lowering therapy
- Fasting 9–12 hours before the blood draw improves triglyceride accuracy; LDL-C can be measured non-fasting
Frequently Asked Questions
Common Questions About LDL vs HDL Cholesterol
What is the difference between LDL and HDL cholesterol?
LDL (low-density lipoprotein) deposits cholesterol into arterial walls and drives atherosclerosis — it is directly causal for cardiovascular disease and the primary drug target. HDL (high-density lipoprotein) is associated with lower cardiovascular risk in population studies, but pharmacologically raising HDL has not reduced cardiac events in clinical trials. LDL is the actionable number; HDL is useful context.
Which cholesterol is more dangerous — LDL or HDL?
High LDL is directly dangerous — every 1 mmol/L increase raises major cardiovascular event risk by approximately 22%. Low HDL is a risk marker, but high HDL does not protect you proportionally: Danish population data of over 116,000 people showed a U-shaped mortality curve, with very high HDL paradoxically associated with increased mortality. The LDL number is the one to act on.
What should my LDL level be in Singapore?
It depends on your cardiovascular risk tier. For most healthy adults: below 3.0 mmol/L (low risk) or 2.6 mmol/L (moderate risk). For diabetics or those with kidney disease: below 1.8 mmol/L. For anyone with a history of heart attack, stroke, or stenting: below 1.4 mmol/L with at least a 50% reduction from baseline. A cardiologist at Paragon Medical Centre can assess your specific risk tier.
Can you have high HDL and still get heart disease?
Yes — and more commonly than patients expect. High HDL does not neutralise high LDL. Mendelian randomisation studies show that genetic variants raising HDL do not reduce cardiovascular events. Very high HDL (above 2.5 mmol/L in men) is paradoxically associated with increased mortality in large population cohorts. Focus on LDL reduction; treat your HDL as useful context, not a safety certificate.
What is non-HDL cholesterol and why does it matter?
Non-HDL cholesterol is total cholesterol minus HDL — it captures every atherogenic lipoprotein, including LDL, VLDL, IDL, and Lp(a). A 2025 systematic review of 593,354 participants found non-HDL and apolipoprotein B to be superior cardiovascular risk predictors compared to LDL-C alone, particularly in statin users. ESC guidelines recommend non-HDL as a secondary target when LDL appears well-controlled.